EUVIMEDEUVIMED entdecken
Open Access

The variable conversion of neutralizing anti-SARS-CoV-2 single-chain antibodies to IgG provides insight into RBD epitope accessibility

Matthew R Chang iD, Hanzhong Ke, Laura Losada Miguéns, Christian Coherd, Katrina Nguyen, Maliwan Kamkaew, Rebecca Johnson, Nadia Storm, Anna Honko, Quan Zhu, Anthony Griffiths, Wayne A Marasco

Protein Engineering, Design and Selection · 2023

DOI: 10.1093/protein/gzad008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Engineering, Design and Selection, 2023. Verfasst von Matthew R Chang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Single-Chain Antibodies, COVID-19. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Massachusetts Consortium on Pathogen Readiness.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibody (mAb) therapies have rapidly become a powerful class of therapeutics with applications covering a diverse range of clinical indications. Though most widely used for the treatment of cancer, mAbs are also playing an increasing role in the defense of viral infections, most recently with palivizumab for prevention and treatment of severe RSV infections in neonatal and pediatric populations. In addition, during the COVID-19 pandemic, mAbs provided a bridge to the rollout of vaccines; however, their continued role as a therapeutic option for those at greatest risk of severe disease has become limited due to the emergence of neutralization resistant Omicron variants. Although there are many techniques for the identification of mAbs, including single B cell cloning and immunization of genetically engineered mice, the low cost, rapid throughput and technological simplicity of antibody phage display has led to its widespread adoption in mAb discovery efforts. Here we used our 27-billion-member naïve single-chain antibody (scFv) phage library to identify a panel of neutralizing anti-SARS-CoV-2 scFvs targeting diverse epitopes on the receptor binding domain (RBD). Although typically a routine process, we found that upon conversion to IgG, a number of our most potent clones failed to maintain their neutralization potency. Kinetic measurements confirmed similar affinity to the RBD; however, mechanistic studies provide evidence that the loss of neutralization is a result of structural limitations likely arising from initial choice of panning antigen. Thus this work highlights a risk of scFv-phage panning to mAb conversion and the importance of initial antigen selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Chain AntibodiesCOVID-19AnimalsMiceHumansEpitopesPandemicsSARS-CoV-2Antibodies, ViralAntibodies, MonoclonalImmunoglobulin GSpike Glycoprotein, CoronavirusAntibodies, Neutralizing

Stichwörter der Autor:innen

SARS-CoV-2antibody discoveryneutralizing antibodiesphage displayphage panning

Substanzen

EpitopesSingle-Chain AntibodiesAntibodies, ViralAntibodies, MonoclonalImmunoglobulin GSpike Glycoprotein, CoronavirusAntibodies, Neutralizingspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Virology, Immunology, and Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, MA 02118, USA.

ORCID-Profile: Matthew R Chang

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Massachusetts Consortium on Pathogen Readiness

Zitieren

APA

Chang, M. R., Ke, H., Losada Miguéns, L., Coherd, C., Nguyen, K., Kamkaew, M., Johnson, R., Storm, N., Honko, A., Zhu, Q., Griffiths, A., & Marasco, W. A. (2023). The variable conversion of neutralizing anti-SARS-CoV-2 single-chain antibodies to IgG provides insight into RBD epitope accessibility. Protein Engineering, Design and Selection. https://doi.org/10.1093/protein/gzad008

Vancouver

Chang MR, Ke H, Losada Miguéns L, Coherd C, Nguyen K, Kamkaew M, et al. The variable conversion of neutralizing anti-SARS-CoV-2 single-chain antibodies to IgG provides insight into RBD epitope accessibility. Protein Engineering, Design and Selection. 2023. doi:10.1093/protein/gzad008

BibTeX
@article{Chang2023,
  author = {Chang, Matthew R and Ke, Hanzhong and Losada Miguéns, Laura and Coherd, Christian and Nguyen, Katrina and Kamkaew, Maliwan and Johnson, Rebecca and Storm, Nadia and Honko, Anna and Zhu, Quan and Griffiths, Anthony and Marasco, Wayne A},
  title = {The variable conversion of neutralizing anti-SARS-CoV-2 single-chain antibodies to IgG provides insight into RBD epitope accessibility},
  journal = {Protein Engineering, Design and Selection},
  year = {2023},
  doi = {10.1093/protein/gzad008}
}
Kostenlos starten →